Canada’s National Advisory Committee on Immunization now recommends expanding the use of the AstraZeneca-Oxford vaccine to all Canadians over the age of 30, but only when the benefits outweigh the risks of rare, serious post-vaccine blood clots.

This entry was posted on Saturday, April 24th, 2021 at 7:13 am and is filed under Finance/ Money. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.